Document:

<PAGE>
                                                                    Exhibit 10.8

                                 FIRST AMENDMENT
                          (LOAN AND SECURITY AGREEMENT)

     THIS FIRST AMENDMENT AGREEMENT (the "Amendment"), dated as of the 2nd of
June, 2003, to that certain Loan and Security Agreement, dated as of January 3,
2003 (the "Loan Agreement"), by and between ClearBlue Technologies, Inc., a
Delaware corporation ("Borrower") and NaviSite, Inc., a Delaware corporation
("Lender"). All capitalized terms used herein without definition shall have the
meanings ascribed to such terms in the Loan Agreement.

     WHEREAS, pursuant to the Loan Agreement, the Lender has loaned to the
Borrower and the Borrower has borrowed from the Lender the sum of ONE MILLION
NINE HUNDRED SIXTY FIVE THOUSAND AND FOUR HUNDRED THIRTY ONE DOLLARS
($1,965,431) in accordance with the terms and provisions of the Loan Agreement;

     WHEREAS, pursuant to the Loan Agreement, the Maximum Loan Amount is US$2
million; and

     WHEREAS, Lender wishes to make available to the Borrower and Borrower
wishes to borrow from the Lender, for a temporary period of up to seven (7)
business days, an ADDITIONAL $250,000 in excess of the Maximum Loan Amount.

     NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:

     1. Amendment. From and after the date hereof for a period of seven (7)
business days, the definition of Maximum Loan Amount in Section 1 of the Loan
Agreement is amended by deleting the words "US$2 million" and inserting in place
thereof the words "US$2.25 MILLION".

     2. No Other Amendments. Except as expressly set forth herein, the Loan
Agreement shall continue in full force and effect without alteration or
amendment.

     3. Validity and Binding Effect. Each party represents, warrants and
confirms that this Amendment is a valid, legal and binding obligation of such
party enforceable in accordance with its terms and that the Loan Agreement is in
full force and effect and has not been supplemented, modified or otherwise
amended, except pursuant to this Amendment or cancelled or terminated.

     4. Amendments. This Amendment and the Loan Agreement may not be further
amended except by written instrument executed by the parties as provided
therein.

<PAGE>

     5. Counterparts. This Amendment may be executed in any number of
counterparts, each of which shall be deemed an original, and all of which, taken
together, shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the Borrower and the Lender, intending to be legally
bound hereby, have executed this First Amendment as of the day and year first
written above.

                                              NAVISITE, INC.

                                              By: /s/ Jim Pluntze
                                                 -------------------------------
                                                 Name: Jim Pluntze
                                                 Title: Chief Financial Officer

                                              CLEARBLUE TECHNOLOGIES, INC.

                                              By: /s/ Arthur Becker
                                                 -------------------------------
                                                 Name: Arthur Becker
                                                 Title: Vice President

                                       2<PAGE>

          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.

                                Exhibit No. 10.22

                Exclusive License and Exclusive Supply Agreement

         This Agreement is made on 20th day of November, 2002 by and between
Matritech, Inc. ("Matritech"), a Delaware corporation having a principal place
of business at 330 Nevada Street, Newton, Massachusetts 02460, U.S.A., and
Sysmex Corporation ("Sysmex"), a Japanese corporation having a principal place
of business at 1-5-1, Wakinohama-kaigandori, Chuo-ku, Kobe, Hyogo 651-0073,
Japan.

         WHEREAS, Matritech has identified certain monoclonal antibodies, called
NMP 179 antibodies, and has proprietary technology in producing and using such
antibodies for the detection of cervical cancer.

         WHEREAS, Sysmex has substantial expertise in the development of
apparatus for medical diagnostics, especially in the automated cellular analysis
areas.

         WHEREAS, Matritech and Sysmex ("the Parties") have been engaged in an
effort for the research, development, commercialization and marketing of a
cervical cancer assessment product.

         WHEREAS, in furtherance of the Parties' effort, the Parties desire that
Matritech provide Sysmex with exclusive supply of the NMP 179 antibodies and the
exclusive worldwide exploitation rights to market, distribute, sell and service
such a cervical cancer assessment product.

         NOW, THEREFORE, in consideration of the promises and mutual covenants
contained herein, the Parties agree as follows:

                               Part I: Definitions

1.       Throughout this Agreement, the following defined terms shall have the
meanings set forth below:

         1.1      "Customers" shall mean an end use customer of Sysmex who
purchases, or is assigned or transferred a Licensed Product from Sysmex

<PAGE>

through a legitimate transaction and uses the Licensed Product in the Field.

         1.2      "Field" shall mean the field of detecting and assessing
cervical cancer including screening using a non-slide-based format, but
specifically excludes detecting and assessing cervical cancer in a slide-based
format.

         1.3      "Licensed Methods" shall mean any and all methods the practice
of which would, in the absence of the license granted hereunder, infringe a
Valid Claim of a Licensed Patent.

         1.4      "NMP 179 antibodies" shall mean [**], called NMP 179 antigens,
produced by Matritech as the raw material of NMP 179 Reagents, and any
improvements thereof.

         1.5      "NMP 179 Reagents" shall mean the reagents used in the Field
which include, but are not limited to, [**].

         1.6      "Licensed Patents" shall mean United States Patent Nos.
5,858,683 and 6,027,905, their foreign counterparts, all reissues and
reexaminations of these United States and foreign patents and all patents that
may issue from patent applications derived from any of the foregoing patents,
including continuations, continuation-in-part applications, divisions, renewals
and extensions of any of the foregoing patent applications and patents.

         1.7      "Licensed Products" shall mean any and all products the
manufacture, use, sale, offer for sale or import of which would, in the absence
of the license granted hereunder, infringe a Valid Claim of a Licensed Patent.

         1.8      "Sysmex" shall mean Sysmex Corporation and its affiliates
which shall mean a corporation performing activities relating to Sysmex's
business in which Sysmex owns and controls, directly or indirectly, at least
fifty percent (50%) of the outstanding shares entitled to vote for the Board of
directors and which agree in writing to be bound by the terms of this Agreement.

         1.9      "Net Sales Value" shall mean [**].

         1.10     "Non-Affiliates" shall mean a company or person other than
Sysmex.

<PAGE>

         1.11     "Valid Claim" shall mean a pending, issued or unexpired patent
claim included among the Licensed Patents so long as such claim has not been
irrevocably abandoned or held to be invalid in an unappealable decision of a
court or other authority of competent jurisdiction.

                            Part I: Exclusive Supply

2.       Exclusive Supply

         2.1      Upon Sysmex's purchase orders, Matritech agrees to manufacture
and sell all NMP 179 antibodies ordered by Sysmex to Sysmex. Sysmex agrees to
purchase such NMP 179 antibodies solely from Matritech pursuant to the terms and
conditions of this entire Agreement. There is no [**] purchase requirement.

         2.2      Matritech agrees that it will not sell NMP 179 antibodies,
whether sold by Matritech itself or sold by a licensee, distributor or any other
third party authorized by Matritech, to any third party in the Field.

         2.3      Sysmex agrees that for so long as Matritech manufactures and
sells the ordered supply of NMP 179 antibodies to Sysmex, and Part I of this
Agreement is effective, Sysmex will fill all of its requirements under this
Agreement including those for NMP 179 antibodies with NMP 179 antibodies
purchased from Matritech.

3.       Order and Purchase

         3.1      All purchases and sales of NMP 179 antibodies between
Matritech and Sysmex shall be initiated by Sysmex's issuance of written purchase
orders sent via airmail or by facsimile. The acceptance by Matritech of a
purchase order from Sysmex shall be indicated by written acknowledgement thereof
by Matritech.

         3.2      Sysmex shall have the right to cancel its purchase order or
any portions thereof for any reason at any time before the purchase order is
accepted pursuant to Subsection 3.1. Sysmex may not cancel its purchase order or
any portions thereof after it is accepted pursuant to Subsection 3.1 unless the
Parties agree on such cancellation.

<PAGE>

4.       Delivery, Shipping and Forecasting

         4.1      Provided the purchase order had been reasonably accurately
forecasted [**] days in advance per Section 4.3, Matritech shall use its best
efforts to ship to Sysmex the ordered NMP 179 antibodies within [**] days after
receiving a purchase order from Sysmex. Matritech will use its best efforts to
ship to Sysmex in such a manner as specified by [**]. All shipping costs shall
be paid by Sysmex.

         4.2      After the ordered NMP 179 antibodies leave the place of
manufacture and prior to delivery to Sysmex, [**] shall be responsible for and
shall bear any and all risk of loss of or damages to the NMP 179 antibodies.

         4.3      Sysmex shall provide Matritech with a unit forecast for the
following [**] months by the first of every three month interval. This is to be
Sysmex's good faith best estimate of their requirements for NMP 179 antibodies
and is not an irrevocable commitment to purchase.

5.       Quality and Inspection

         5.1      Matritech agrees to meet, for every purchase order from
Sysmex, mutually acceptable predetermined requirements on the quality of NMP 179
antibodies.

         5.2      Matritech agrees that all NMP 179 antibodies manufactured and
delivered by Matritech shall be subject to receiving inspection by Sysmex.

         5.3      Within [**] days of the date of delivery of ordered NMP 179
antibodies to Sysmex, including an order repaired or replaced under this
Subsection, Sysmex shall inspect the received order for satisfaction of the
required quality, damage incurred during shipping and conformity to the purchase
order. If Sysmex and Matritech mutually agree that the order Sysmex has received
does not satisfy the required quality, conform to the purchase order or is
damaged during shipment, Sysmex shall notify Matritech in writing within forty
five (45) days of the date of the delivery to Sysmex, and Matritech shall at its
own expense repair or replace such order, which shall be Matritech's sole
liability for such non-conformity to quality standards or damage.

<PAGE>

6.       Payment

         6.1      The Parties agree that the purchase price of NMP 179
antibodies Sysmex will pay to Matritech is equal to [**]. Production cost shall
be limited only to [**] allocated in accordance with the generally accepted
accounting principles.

         6.2      The production cost of NMP 179 antibodies shall be determined
by Matritech and verified by Sysmex once a year and used to calculate purchase
prices of Subsection 6.1 for a twelve-month period to come until it is replaced
by a new production cost determined and approved for the next twelve-month
period.

         6.3      The twelve-month period as set forth in Subsection 6.2 begins
from January 1 and ends on December 31 of the same year. The production cost
used to calculate purchase prices of Subsection 6.1 is a production cost that is
valid when the purchase order is placed by Sysmex provided the requested
delivery date on such purchase order is sixty (60) days or less.

         6.4      By thirty (30) days before January 1 every year, Matritech
shall determine its production cost of NMP 179 antibodies used to calculate
purchase prices of Subsection 6.1 for a next twelve-month period and notify it
to Sysmex, along with appropriate documentation on which the determination of
the production cost is based.

         6.5      Within [**] days subsequent to the end of the thirty-day time
period set forth in Subsection 5.3, Sysmex shall make a payment to a purchase
order through a wire-transfer to the designated bank account.

         6.6      An amount of payment made pursuant to Subsection 6.5 shall be
equal to the purchase price determined pursuant to Subsections 6.1-6.4. Deducted
from the payment are any taxes withheld according to the United States-Japan
Income Tax Treaty (the "Treaty") provided that Sysmex uses its reasonable best
efforts to reduce its withholding obligation pursuant to the Treaty. If Sysmex
withholds any taxes according to the tax treaty, Sysmex shall provide Matritech
with an official certificate of such taxes withheld issued by the appropriate
authority of the Japanese government and any other information that Matritech
may reasonably request concerning the taxes withheld.

<PAGE>

7.       Term of Part I of this Agreement

         7.1      Unless terminated earlier pursuant to this Agreement, Part I
of this Agreement shall continue in force until all of the Licensed Patents
expire or become no longer legally effective. Following such period the Part I
of this Agreement will automatically renew for another one year unless either
party gives a 60-day advance notice in writing advising the other party that it
will not renew Part I of this Agreement.

         7.2      Unless the entire Agreement is terminated pursuant to this
Agreement, Part I of this Agreement shall survive expiration or termination of
Part II of this Agreement.

8.       Stable and Sufficient Supply

         8.1      Matritech shall provide stable and sufficient supply of NMP
179 antibodies to Sysmex.

         8.2      If Matritech fails to provide Sysmex with all its required
supply of reasonably accurately forecasted NMP 179 antibodies ordered pursuant
to Part I of this Agreement on any particular purchase order, following written
notice and a reasonable period of cure, such failure may constitute a reason for
Sysmex to terminate Part I of this Agreement.

         8.3      If Part I of this Agreement is terminated for Matritech's
failure to supply NMP 179 antibodies in accordance with Part I of this
Agreement, Sysmex shall be entitled to obtain from Matritech the entire cell
line (hybridoma), protocols and technologies for producing NMP 179 antibodies
without further consideration. In the event that Matritech fails to supply NMP
179 antibodies and Sysmex obtains the hybridoma for producing NMP 179
antibodies, then Matritech will no longer be entitled to the payments described
in Section 6 but will remain entitled to all other payments and royalties
described in this Agreement.

         8.4      Matritech agrees to place the entire cell line (hybridoma) and
protocols into the possession of a mutually agreeable third party escrow service
which will transfer the cell line and the protocols to Sysmex in the event set
forth in Subsection 8.3. To this effect, Matritech and Sysmex shall prepare and
execute an escrow agreement within a reasonably short time after the execution
of this Agreement.

<PAGE>

The escrow agreement executed by the parties shall be attached to this Agreement
and become part of this Agreement.

                      Part II: EXCLUSIVE LICENSE AGREEMENT

9.       Exclusive License

         9.1      Matritech hereby grants Sysmex the sole and exclusive
worldwide license under the Licensed Patents to: (a) make, have made, use, sell,
offer to sell, lease or otherwise dispose of Licensed Products in the Field; (b)
practice a Licensed Methods in the Field; and (c) sell products or parts for use
in practicing a Licensed Methods in the Field.

         9.2      Matritech represents and agrees that it has not and will not
grant any third parties a license within the Field under any of the Licensed
Patents before Part II of this Agreement becomes no longer effective or is
terminated.

         9.3      The exclusive license granted to Sysmex under Subsection 9.1
includes the right to sublicense provided that (i) granting of such sublicense
has to be approved in advance by Matritech and (ii) sublicensees granted such
sublicense will not market NMP 179 Reagents so as not to affect Matritech
absolute revenues under this Agreement. Besides sublicenses expressly granted by
Sysmex under this subsection, sale, assignment or transfer of a Licensed
Product, or a product or part for use in practicing a Licensed Method, through a
legitimate transaction from Sysmex to a Customer and a Non-Affiliate will carry
the right for the Customer to use the Licensed Product or the product or part,
free of infringement claims under any of the Licensed Patents and the right for
the Non-Affiliate to resell the Licensed Product or the product or part, free of
infringement claims under any of the Licensed Patents.

         9.4      Matritech agrees that under any patents that Matritech has
licensing rights to other than the Licensed Patents owned by Matritech, or
assigned or transferred from Matritech that are or will necessarily be infringed
by use of a Licensed Product or practice of a Licensed Method, Sysmex shall have
a non-exclusive, royalty-free, non assignable

<PAGE>

or transferable license for the terms of such patents to the extent that Sysmex
exercises its rights granted under the Licensed Patents pursuant to Subsection
9.1. Matritech further agrees that under the same patents, the sublicensees who
have a sublicense pursuant to Subsections 9.3 and the Customers and the
Non-Affiliates as described in the same Subsection shall have a non-exclusive,
royalty-free, no assignable or transferable license for the term of the patents
to the extent that the sublicensees exercise its rights granted under the
sublicenses.

         9.5      Matritech agrees to assist Sysmex in recording the existence
of the exclusive licenses granted to Sysmex under Subsection 9.1 at the Patent
Office in countries in relation to the Licensed Patents according to the
applicable recordation laws and rules of the countries.

10       Royalties

         10.1     Sysmex shall pay to Matritech [**] percent ([**]%) of the Net
Sales Value.

         10.2     Sysmex shall keep and maintain a record on sales of NMP 179
Reagent to Non-Affiliates and prepare, from the record kept and maintained under
this Subsection, a quarterly report showing the sales of NMP 179 Reagent during
each of three-month periods starting from January 1 and ending on December 31 of
the same year. Sysmex shall provide a quarterly report prepared under this
Subsection to Matritech on or before the 30th day of the first month after each
three-month period ends.

         10.3     Concurrent with providing a quarterly report to Matritech
pursuant to Subsection 10.2, Sysmex shall make a payment through a wire-transfer
to the designated bank account.

         10.4     An amount of payment made pursuant to Subsection 10.3 shall be
equal to [**]% of the Net Sales Value determined in a quarterly report as set
forth in Subsection 10.2. Deducted from a payment are any taxes withheld
according to the Treaty. If Sysmex withholds taxes according the tax treaty,
Sysmex shall provide Matritech with an official certificate of such taxes
withheld issued by the appropriate

<PAGE>

authority of the Japanese government and any other information that Matritech
may reasonably request concerning the taxes withheld.

11.      Patent Filing and Maintenance

         Matritech will be primarily responsible at its own expense for the
preparation, filing, prosecution and maintenance of all patent applications and
patents within the Licensed Patents. Matritech shall keep Sysmex informed of the
progress of all patent applications within the Licensed Patents, and shall give
Sysmex reasonable opportunity to comment on the type and scope of useful claims,
patent filings, and prosecution strategy.

12.      Infringement of the Licensed Patents by Third Parties

         12.1     Each party shall notify the other within thirty (30) days of
obtaining knowledge of a possible infringement of the Licensed Patents in the
Field.

         12.2     Matritech shall have the sole right, but not the obligation,
at its own expense, to take all steps that, in Matritech's sole discretion, are
necessary or appropriate to protect and to enforce any of the Licensed Patents
in the Field, including the initiation of legal proceedings against any third
party who has infringed or ever infringes any Licensed Patents within the Field.
Any damage, cost, award fee, recovery, or compensation paid by any third party
in connection with any proceeding initiated or carried on at Matritech's expense
(whether by way of settlement or otherwise) shall be retained by Matritech.
Matritech shall not enter into any settlement, consent judgment, or any other
voluntary final disposition of any infringement action under this section
without the prior written consent of Sysmex, which consent shall not be
unreasonably withheld, conditioned or delayed.

         12.3.    In the event that Matritech elects not to initiate legal
proceedings under section 12.2, Matritech shall provide prompt written notice of
such to Sysmex, and Sysmex shall have the right, but not the obligation, to
initiate legal proceedings against the infringer in the Field at Sysmex's sole
expense, naming Matritech as a party, if so required by law. Matritech agrees to
become a named party of such

<PAGE>

legal proceedings if so requested by Sysmex. Any damage, cost, award fee,
recovery, or compensation paid by any third party in connection with any
proceeding initiated or carried on at Sysmex's expense pursuant to this section
(whether by way of settlement or otherwise) shall be retained by Sysmex. Sysmex
shall not enter into any settlement, consent judgment, or any other voluntary
final disposition of any infringement action under this section without the
prior written consent of Matritech, which consent shall not be unreasonably
withheld, conditioned or delayed.

         12.4     In the event that any party ("Initiating Party") desires to
initiate, initiates, or carries on any legal proceeding to enforce or to protect
any of the Licensed Patents under sections 12.2 and 12.3, the other party
(Non-initiating Party) hereto shall fully co-operate with and will supply all
assistance reasonably requested by the initiating party. The Initiating Party
shall have sole control of the proceeding and shall bear reasonable expenses
(excluding legal fees) incurred by the Non-initiating Party in providing such
assistance and cooperation as the Initiating Party may request. The
Non-initiating Party shall be entitled to participate in any proceedings
initiated or carried on by the Initiating Party with counsel selected by it, but
at its own expense.

13.      Term of Part II of this Agreement

         13.1     Unless terminated earlier pursuant to this Agreement, Part II
of this Agreement shall continue in force until all of the Licensed Patents
expire or become no longer legally effective.

         13.2     Unless the entire Agreement is terminated pursuant to this
Agreement, Part II of this Agreement shall survive expiration or termination of
Part I of this Agreement.

14.      Election To Continue Under this Agreement

         In the event that Matritech seeks or is involuntarily placed under the
protection of the bankruptcy laws, Title XI, U.S. Code, and the trustee rejects
this Agreement, Sysmex hereby elects, pursuant to

<PAGE>

section 365(n) to retain all rights granted to it under this Agreement to the
extent permitted by law.

                          Part III: General Provisions

15.      Applicability of Part III of this Agreement

         Except as specified otherwise, Part III of this Agreement applies to
the entire Agreement including Part I and Part II of this Agreement.

16.      Other Payments

         16.1(a)  In addition to the payments made from Sysmex to Matritech
pursuant to the other sections of this Agreement, Sysmex shall make the
following payments to Matritech:

         (i)      Sysmex shall subscribe newly issued shares of common stock of
Matritech at a premium of 33% over the Market Price. The "Market Price" shall
mean the average of the closing prices of Matritech's common stock on the NASDAQ
(stock market) for the period between October 15 and November 15 of 2002. The
total amount subscribed and paid in by Sysmex under this Subsection shall be
$2,000,000 and it shall be due upon signing the Agreement. Upon receipt of the
amount of $2,000,000, Matritech shall deliver to Sysmex the share certificate
representing the number of shares (the "Shares") calculated accordingly; by
dividing (X) $2,000,000 by (Y) the product of 1.33 times the Market Price. The
stock purchase under this Subsection shall be subject to Sysmex's conducting the
necessary due diligence

         (ii)     Sysmex shall pay $[**] upon United States Food and Drug
Administration's first approval for the Licensed Products for detecting and
assessing cervical cancer on a [**] basis; and

         (iii)    Sysmex shall pay $[**] on the three-year anniversary of the
date when Sysmex launches its marketing of the Licensed Products, or on the date
when Sysmex achieves its sales of the Licensed Products over $[**], whichever
comes first.

         16.1(b)  Sysmex hereby represents and warrants to Matritech, on behalf
of itself and any affiliate that may be acquiring the Shares, that:

<PAGE>

         (i)      it is an "accredited investor" within the meaning of Rule 501
promulgated under the Securities Act of 1933, as amended (the "Securities Act")
and was not organized for the specific purpose of acquiring the Shares;

         (ii)     it has sufficient knowledge and experience in investing in
companies similar to Matritech so as to be able to evaluate the risks and merits
of its investment in Matritech and it is able financially to bear the risks
thereof;

         (iii)    it has had an opportunity to (a) discuss Matritech's business,
management and financial affairs with Matritech's management, (b) ask questions
and receive answers concerning the terms of the issuance of the Shares and (c)
obtain any additional information it desires concerning Matritech that Matritech
possesses or can acquire without unreasonable effort or expense;

         (iv)     the Shares being purchased by it are being acquired for its
own account for the purpose of investment and not with a view to or for sale in
connection with any distribution thereof;

         (v)      it understands that (a) the Shares have not been registered
under the Securities Act by reason of their issuance in a transaction exempt
from the registration requirements of the Securities Act pursuant to Section
4(2) thereof or pursuant to Rules 505 or 506 promulgated under the Securities
Act, (b) the Shares must be held indefinitely unless a subsequent disposition
thereof is registered under the Securities Act or is exempt from such
registration, (c) the Shares will bear a legend to such effect and (d) Matritech
will make a notation on its transfer books to such effect.

         16.1(c)  Sysmex agrees, without the prior written consent of Matritech,
not to sell, offer to sell, contract to sell, transfer or otherwise dispose of:

         (i)      [**] of the Shares prior to approval by the United States Food
and Drug Administration, as described above in Section 16.1(a)(ii); or

         (ii)     more than [**] of the Shares prior to the achievement of the
milestone described in section 16.1(a) (iii).

After the achievement of the milestone in section 16.1(a) (iii) or if the entire
Agreement is terminated by either party, Sysmex shall be

<PAGE>

permitted to sell, offer to sell, contract to sell, transfer or otherwise
dispose of any or all of the Shares, subject only to compliance with applicable
securities laws. If Sysmex is unable at any time to sell such number of Shares
as may be permitted under this Agreement by reason of restrictions on resale
under U.S. securities laws, Matritech will use its best efforts to register such
Shares at Matritech's expense, under the Securities Act for resale by Sysmex.

         16.2     In addition to the payments made from Sysmex to Matritech
pursuant to Subsection 16.1 and the other sections of this Agreement, Sysmex
shall pay Matritech a minimum of $[**] per quarter for services of development
whether or not such services are rendered for a time period starting from the
effective date of this Agreement through the date when marketing of the Licensed
Products is launched in the United States. Matritech agrees to render such
services as reasonably requested by Sysmex. Sysmex will pay Matritech, at a
reasonable rate, any quarterly cost expended by Matritech in excess of $[**] for
services of development, provided that such services are rendered with Sysmex's
advance authorization.

17.      Warranties, Limits of Liability, Indemnification, and Insurance

         17.1     Matritech warrants that to the best of its knowledge, it has
the power to enter into this Agreement and that it has no knowledge of any
action or claim instituted or threatened by a third party against any of the
Licensed Patents.

         17.2     Matritech further warrants that, to the best of its knowledge,
the NMP 179 antibodies actually provided by Matritech do not infringe any
patent, copyright, trademark or other intellectual property right of any third
party in existence on the date of execution of this Agreement.

         17.3     EXCEPT AS SPECIFICALLY SET FORTH IN SECTIONS 17.1 and 17.2,
MATRITECH MAKES NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED,
REGARDING (1) THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, OR (2) THE
VALIDITY, ENFORCEABILITY OR SCOPE OF THE LICENSED PATENTS. ALSO, EXCEPT AS
SPECIFICALLY SET FORTH IN SECTIONS 17.1 AND 17.2, MATRITECH SPECIFICALLY
DISCLAIMS ANY IMPLIED WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE.

<PAGE>

         17.4     MATRITECH'S TOTAL LIABILITY ARISING OUT OF THIS AGREEMENT
SHALL BE LIMITED TO THE AMOUNT HAVING THEN ACTUALLY BEEN PAID BY SYSMEX TO
MATRITECH UNDER THIS AGREEMENT. IN NO EVENT SHALL MATRITECH BE LIABLE TO SYSMEX
OR ANY OTHER ENTITY FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL,
MULTIPLE, PUNITIVE OR OTHER DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF
LIABILITY, AND WHETHER OR NOT FOR BREACH OF CONTRACT, NEGLIGENCE OR OTHERWISE,
AND WHETHER OR NOT MATRITECH HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.
THESE LIMITATIONS WILL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF
ANY LIMITED REMEDY PROVIDED HEREIN. MATRITECH'S LIMITATION OF LIABILITY IS
CUMULATIVE, WITH ALL OF MATRITECH'S EXPENDITURES BEING AGGREGATED TO DETERMINE
SATISFACTION OF THE LIMIT.

         17.5     Sysmex shall defend, indemnify and hold harmless Matritech,
its directors, officers, employees, and agents and their respective successors,
heirs and assigns from and against any and all claims, demands, suits, actions,
or proceedings brought by any third party (i) arising out of product liability
and personal injury, death and/or property damage in connection with the use of
a Licensed Product or (ii) based on a claim that the Licensed Product, or the
use or sale thereof by Sysmex under this Agreement infringes any patent,
copyright, tradesecret, trademark, or other intellectual property right of any
third party. Sysmex, however, shall not be required to defend, indemnify and
hold harmless Matritech, or any other indemnified party, to the extent such
claims, demands, suits, actions or proceedings are determined with finality by a
court of competent jurisdiction to have resulted from the negligent, reckless or
intentional act or omission of Matritech or any other indemnified party. Such
indemnity obligation is contingent on prompt written notice of any claim, action
or demand for which indemnity is claimed, reasonable co-operation (at Sysmex's
expense) of Matritech in such defense, and complete control of the defense and
settlement thereof, except that Sysmex will not have the right to make any
monetary settlement or take any other action which would include any admission
of liability on the part of Matritech its directors, officers, employees, and
agents and their respective successors, heirs and assigns without the prior
written consent of the

<PAGE>

party involved, which consent shall not be unreasonably withheld or delayed.

         17.6     The parties agree that at least [**] prior to the date any
Licensed Product or Licensed Method is used in human clinical trial for FDA
submission, the parties shall negotiate in good faith and agree upon the terms
of a commercial, general liability insurance policy to protect Matritech with
regard to the events described in Subsection 17.5

18.      Term of the entire Agreement

         18.1     The entire Agreement shall become effective upon the date
first appearing above and, except as otherwise terminated earlier pursuant to
this Agreement, shall continue in force until both Part I and Part II of this
Agreement expire or are terminated.

         18.2     If one of Part I and Part II of this Agreement expires or is
terminated, or otherwise loses its legal effect, the other part may be
terminated with the consent of the Parties.

         18.3     Sysmex is to use its best efforts in bringing Licensed
Products to market. If Sysmex is unable to bring Licensed Products to the United
States market by the end of [**], Matritech and Sysmex will in good faith
discuss any extension of time at the end of [**] as long as Sysmex has been
diligently working on bringing Licensed Products to the market.

19.      Termination

         19.1     Except as otherwise provided herein, this Agreement may be
terminated by written agreement of both Parties signed by their authorized
officers or representatives.

         19.2     If one of the Parties becomes the subject of a voluntarily or
involuntarily petition in bankruptcy or any proceeding relating to insolvency,
receivership, liquidation or composition of the benefit of creditors, which
petition or proceeding is not dismissed with prejudice within sixty (60) days
after filing, the other Party may terminate Part I, Part II or both Part I and
Part II at its option.

         19.3     If one of the Parties breaches any material term or condition
of this Agreement and fails to cure that breach within sixty (60) days after
receiving written notice of the breach, the non-breaching Party

<PAGE>

may terminate the entire Agreement. The terminating party shall have all rights
and remedies available at law or equity as well as any other rights and remedies
set forth in this Agreement.

20.      Confidential Information

         20.1     For purpose of hereof, the term "Confidential Information" as
applicable to each Party shall mean all business and financial information
relating to that Party, all proprietary information relating to the Licensed
Patents and any products or processes produced in connection with the Licensed
Patents, and all inventions, discoveries, methods, plans, techniques, processes,
documents, drawings, data, samples, patent applications, trade secrets,
know-how, and information of the applicable party that is related thereto and
marked "Confidential."

         20.2     The Confidential Information shall not include anything that:

         (i)      is or lawfully becomes in the public domain, other than as a
result of a breach of an obligation hereunder;

         (ii)     is furnished to the recipient by a third party having a lawful
right to do so; or

         (iii)    was known to the recipient at the time of the disclosure.

         20.3     Each Party hereto shall for the term of this entire Agreement
and for a period of two years thereafter:

         (i)      treat as confidential and preserve the confidence of all
Confidential Information of the other party;

         (ii)     make no use of the other Party's Confidential Information
except as expressly permitted under this Agreement; and

         (iii)    limit access to the other Party's Confidential Information to
the recipient's employees who reasonably require access to such Confidential
Information.

         20.4     Upon termination of the entire Agreement, each party shall
promptly deliver to the other Party all tangible embodiments, including all
copies, of the other Party's Confidential Information; provided, however, that
each party shall be entitled to keep one copy of such Confidential Information
as necessary for proper business purposes as

<PAGE>

long as it continues to follow the confidentiality obligations under this
Section.

         20.5     There is not an adequate remedy at law for a breach of this
Section, and Matritech or Sysmex will suffer irreparable harm as a result of
such a breach. Therefore, if a breach or threatened breach by either Party of
this Section occurs, in addition to any other rights and remedies it may have,
the non-breaching party shall be entitled to injunctive relief restraining the
breaching party from doing any act in violation of this Section without the
requirement of posting bond, cash or otherwise.

21.      Intellectual Property

         The Parties agree that any intellectual property, including without
limitation inventions, discoveries, designs, trade secrets, know-how and other
forms of proprietary information, that is made, created, or developed solely by
one Party in relation to any of the Licensed Patents, the Licensed Methods and
the Licensed Products will belong to such one Party.

22.      Survival

         The provisions of this Agreement that, by their sense and context are
intended to survive performance by either or both Parties, shall also survive
the completion, expiration, termination or cancellation of this Agreement.

23.      Successors and Assigns

         Neither party shall assign this Agreement or any of the rights,
interests or obligations hereunder either in whole or in part, without the prior
written consent of the other party hereto, except that Matritech's rights and
obligations under this agreement may be assigned to any entity that acquires
substantially all of the business relating to this Agreement, which entity shall
agree in writing to be bound by the terms of this Agreement.

<PAGE>

24.      No joint venture

         Nothing contained in this Agreement shall be deemed or construed as
creating a joint venture or partnership between the Parties. Neither party shall
have the power to control the activities or operations of the other party.
Neither party shall hold itself out as having authority or relationship in
contravention of this Section.

25.      Entire Agreement

         This Agreement constitutes the entire agreement between the Parties
relating the subject matter thereof. All prior or contemporaneous agreements,
whether written or oral, between the Parties, or their agents and
representatives to the subject hereof are merged into this Agreement. This
Agreement may be altered or amended only by an instrument in writing signed by
all the Parties hereto.

26.      Severability

         If any term or provision of this Agreement shall, to any extent, be
determined to be invalid or unenforceable by a court or body of competent
jurisdiction, the reminder of this Agreement shall not be affected thereby, and
each term and provision of this Agreement shall be valid and enforceable to the
fullest extent permitted by law.

27.      Applicable Law

         The validity, interpretation, enforceability and performance of this
Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, U.S.A. without regard to the conflicts of law
principles.

28.      Settlement of Dispute

         28.1     The Parties shall confer in good faith to attempt to resolve
any disputes or controversies arising out of or relating to this Agreement and
attempt to negotiate any term, condition, right or obligation not set forth in
this Agreement.

         28.2     If such attempt fails, all matters of concern shall be
submitted to Arbitration, which shall be conducted either in Boston,
Massachusetts if Sysmex requests such Arbitration or in Osaka, Japan if Matitech
requests such Arbitration by a panel of three arbitrators pursuant to the rules
of the International Chamber of Commerce and shall be final and binding on all
the parties.

<PAGE>

29.      Force Majeure

         Neither party shall be liable for delay or failure in the performance
of its obligations hereunder if such delay or failure arises from the occurrence
of evens beyond the reasonable control of such party, such as fire, flood,
earthquake, storm, government regulations or the intervention of any government
authority. In such case, the parties hereto may confer to alter this Agreement.

30.      Patent Marking

         Sysmex shall apply the patent marking notices in accordance with the
applicable patent laws of countries where Licensed Products are made, sold or
used to the extent commercially feasible as consistent with prevailing business
practices.

31.      The terms of this Agreement are confidential and shall not be disclosed
to any third party, except as required by the law or regulations, without the
prior written consent of the other party.

32.      This Agreement may be executed in any number of counterparts, each of
which shall be considered an original, and all of which together shall be deemed
to be one and the same instrument.

MATRITECH, INC.                                      SYSMEX CORPORATION
By: /s/ Stephen D. Chubb                             By: /s/ Hisashi Ietsugu
Print: Stephen d. Chubb                              Print: Hisashi Tetsugu
Title: Director, Chairman,                           Title: President and CEO
 and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00053-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00053-of-00352.parquet"}]]